A functional and mechanistic explanation for the unique clinical success of the glucokinase activator dorzagliatin for treatment of type 2 diabetes
Diabetes. 2025 Apr 24:db250066. doi: 10.2337/db25-0066. Online ahead of print.ABSTRACTGlucokinase activators (GKA) are a long-sought therapeutic modality for the treatment of Type 2 Diabetes (T2D). However, all GKAs failed clinical trials, with the recent exception of dorzagliatin (Hua Medicine). A